Herz-Kreislauf-Check -- Cardiovascular Check

Cardiovascular risk panel combining a large blood count, lipid profile, fasting glucose, creatinine, and three advanced cardiac markers -- HbA1c, Lipoprotein(a), and high-sensitivity CRP. These markers go beyond a standard lipid panel to capture long-term glycaemic control, genetic lipid risk, and vascular inflammation. Priced at approximately EUR 77 under GOAe 1.0x rates.

The Herz-Kreislauf-Check targets cardiovascular disease -- the leading cause of death in Germany, accounting for roughly one-third of all mortality. The panel builds on the standard lipid profile with three markers that substantially improve risk prediction beyond traditional cholesterol measurement. HbA1c (glycated haemoglobin) reflects average blood glucose over the preceding 8-12 weeks, unaffected by meal timing or daily fluctuation. An HbA1c of 6.5% or above is diagnostic of type 2 diabetes, while 5.7-6.4% identifies pre-diabetes. Diabetes doubles cardiovascular risk independently of lipid levels, making long-term glycaemic assessment essential for comprehensive cardiac risk stratification. Lipoprotein(a) is a genetically determined lipoprotein particle that is an independent and causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve stenosis. Unlike LDL cholesterol, Lp(a) levels are largely fixed by genetics and are not meaningfully modified by diet or statin therapy. The European Atherosclerosis Society recommends measuring Lp(a) at least once in every adult's lifetime. Levels above 50 mg/dL (approximately 125 nmol/L) confer significantly elevated risk and may influence treatment intensity decisions, including consideration of PCSK9 inhibitors. High-sensitivity CRP (hsCRP) measures low-grade systemic inflammation. CRP is synthesised by the liver in response to interleukin-6 and directly participates in atherogenesis. The JUPITER trial demonstrated that statin therapy benefits patients with elevated hsCRP even when LDL cholesterol is within normal range. Values below 1 mg/L indicate low cardiovascular risk, 1-3 mg/L moderate risk, and above 3 mg/L high risk. The large blood count provides the haematological baseline, while the full lipid panel (total cholesterol, HDL, LDL, triglycerides) and fasting glucose complete the standard risk factor assessment. Creatinine with eGFR screens for renal dysfunction, which is both a consequence and an independent risk factor for cardiovascular disease. At GOAe 1.0x rates, the total cost including blood draw and outpatient fees comes to approximately EUR 77 -- a fraction of what a cardiologist consultation with equivalent testing would cost at the standard 2.3x GOAe multiplier.